Correspondence 0001193125-24-269904 from Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc.
Date: Dec. 3, 2024 · CIK: 0001750149 · Accession: 0001193125-24-269904
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283307
Letter
Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway SE, Suite 1900
Atlanta, GA 30339
December 3, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Alan Campbell
Re:
Inhibikase Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 18, 2024
File No. 333-283307
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inhibikase Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-283307) (the “Registration Statement”) be accelerated so that the Registration Statement will become effective on Thursday, December 5, 2024 at 4:30 p.m. (Eastern Time), or as soon thereafter as practicable.
Please feel free to direct any questions or comments concerning this request to Todd Kornfeld, Esq. of McDermott Will & Emery LLP at (212) 547-5890.
The Company understands that the staff of the United States Securities and Exchange Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
INHIBIKASE THERAPEUTICS, INC.
By:
/S/ MILTON H. WERNER
Name:
Milton H. Werner, Ph.D.
Title:
President and Chief Executive Officer
cc: Todd Kornfeld, McDermott Will & Emery LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 December 3, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Alan Campbell Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-3 Filed November 18, 2024 File No. 333-283307 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inhibikase Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-283307) (the “Registration Statement”) be accelerated so that the Registration Statement will become effective on Thursday, December 5, 2024 at 4:30 p.m. (Eastern Time), or as soon thereafter as practicable. Please feel free to direct any questions or comments concerning this request to Todd Kornfeld, Esq. of McDermott Will & Emery LLP at (212) 547-5890. The Company understands that the staff of the United States Securities and Exchange Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. INHIBIKASE THERAPEUTICS, INC. By: /S/ MILTON H. WERNER Name: Milton H. Werner, Ph.D. Title: President and Chief Executive Officer cc: Todd Kornfeld, McDermott Will & Emery LLP